Downloads: 175

Files in This Item:
File Description SizeFormat 
s10147-013-0578-x.pdf457.83 kBAdobe PDFView/Open
Title: A single-center analysis of the survival benefits of adjuvant gemcitabine chemotherapy for biliary tract cancer.
Authors: Yamanaka, Kenya
Hatano, Etsuro
Kanai, Masashi  kyouindb  KAKEN_id
Tanaka, Shiro  kyouindb  KAKEN_id
Yamamoto, Keiichi
Narita, Masato
Nagata, Hiromitsu
Ishii, Takamichi  kyouindb  KAKEN_id  orcid (unconfirmed)
Machimoto, Takahumi
Taura, Kojiro
Uemoto, Shinji
Author's alias: 波多野, 悦朗
Keywords: Gemcitabine
Adjuvant chemotherapy
Biliary tract cancer
Issue Date: Jun-2014
Publisher: Springer Japan
Journal title: International journal of clinical oncology
Volume: 19
Issue: 3
Start page: 485
End page: 489
Abstract: [Background]Surgical resection is the only curative treatment of biliary tract cancer (BTC). However, the prognosis of BTC remains unsatisfactory. The aim of this study is to evaluate the benefits of adjuvant gemcitabine chemotherapy for BTC. [Methods]We performed a historical cohort study that involved 198 patients who underwent R0 surgical resection. Patients who underwent major hepatectomy were administered biweekly intravenous gemcitabine at a dose of 800 mg/m2. Otherwise, patients were administered intravenous gemcitabine at a dose of 1, 000 mg/m2 in 3 weekly infusions, which were followed by a 1-week pause. The primary outcome was overall survival. The hazard ratio (HR) of adjuvant chemotherapy was estimated by propensity score-stratified Cox regression that was adjusted for confounders. [Results]Forty patients received adjuvant chemotherapy. The HR of adjuvant chemotherapy was 0.47 [95 % confidence interval (CI) 0.28–0.95; P = 0.03]. Subgroup analysis showed that the survival benefits were possibly modified by lymph node positivity (HR 0.19; 95 % CI 0.07–0.58; interaction, P = 0.22), stage III (HR 0.11; 95 % CI 0.02–0.50; interaction, P < 0.01), intrahepatic cholangiocarcinoma (ICC) (HR 0.09; 95 % CI 0.01–0.67; interaction, P = 0.05), and poorly differentiated tumor (HR 0.16; 95 % CI 0.03–0.85; interaction, P = 0.13). [Conclusions]Adjuvant gemcitabine chemotherapy for BTC may be effective, particularly for patients with stage III and ICC.
Rights: The final publication is available at Springer via
この論文は出版社版でありません。引用の際には出版社版をご確認ご利用ください。This is not the published version. Please cite only the published version.
DOI(Published Version): 10.1007/s10147-013-0578-x
PubMed ID: 23765238
Appears in Collections:Journal Articles

Show full item record

Export to RefWorks

Export Format: 

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.